These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 29762727)

  • 21. Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.
    Chae YK; Pan A; Davis AA; Mohindra N; Matsangou M; Villaflor V; Giles F
    Clin Lung Cancer; 2017 Mar; 18(2):132-140. PubMed ID: 27520630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy.
    Jiang Y; Xie J; Cheng Q; Cai Z; Xu K; Lu W; Wang F; Wu X; Song Y; Lv T; Zhan P
    Int Immunopharmacol; 2024 Nov; 141():112901. PubMed ID: 39151386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of immunotherapy in small cell lung cancer.
    Calles A; Aguado G; Sandoval C; Álvarez R
    Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for small cell lung cancer: established applications and novel approaches.
    Scott SC; Hann CL
    Clin Adv Hematol Oncol; 2021 Oct; 19(10):654-663. PubMed ID: 34637432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
    Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell Lung Cancer (SCLC).
    Grenda A; Krawczyk P; Obara A; Gajek Ł; Łomża-Łaba A; Milanowski J
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients.
    Jiang Y; Chen Y; Cheng Q; Lu W; Li Y; Zuo X; Wu Q; Wang X; Zhang F; Wang D; Wang Q; Lv T; Song Y; Zhan P
    Cancer Immunol Immunother; 2024 Oct; 73(12):241. PubMed ID: 39358575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in Lung Cancer: From a Minor God to the Olympus.
    Russo A; McCusker MG; Scilla KA; Arensmeyer KE; Mehra R; Adamo V; Rolfo C
    Adv Exp Med Biol; 2020; 1244():69-92. PubMed ID: 32301011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer.
    Khadela A; Postwala H; Rana D; Dave H; Ranch K; Boddu SHS
    Med Oncol; 2023 Apr; 40(5):152. PubMed ID: 37071269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.
    Carbotti G; Nikpoor AR; Vacca P; Gangemi R; Giordano C; Campelli F; Ferrini S; Fabbi M
    J Exp Clin Cancer Res; 2017 Oct; 36(1):140. PubMed ID: 29020964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
    Li W; Ye L; Huang Y; Zhou F; Wu C; Wu F; He Y; Li X; Wang H; Xiong A; Gao G; Wang L; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2022 May; 167():25-33. PubMed ID: 35381444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
    Sharp A; Bhosle J; Abdelraouf F; Popat S; O'Brien M; Yap TA
    Eur J Cancer; 2016 Jun; 60():26-39. PubMed ID: 27060747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Advances of immunotherapy in small cell lung cancer].
    Liu J; Zhang S; Li H; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2014 Jun; 17(6):474-80. PubMed ID: 24949688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
    Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
    Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immune Characteristics of Small Cell Lung Cancer].
    Zhu Y; Wu S
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):889-896. PubMed ID: 33070515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer.
    Zugazagoitia J; Osma H; Baena J; Ucero AC; Paz-Ares L
    Clin Cancer Res; 2024 Jul; 30(14):2872-2883. PubMed ID: 38630789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breaking the Impasse: Advances in Treatment of Small Cell Lung Cancer.
    Saltos A; Antonia S
    Clin Chest Med; 2020 Jun; 41(2):269-280. PubMed ID: 32402362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized Therapy of Small Cell Lung Cancer.
    Schneider BJ; Kalemkerian GP
    Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
    Mak DWS; Li S; Minchom A
    Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.